Fletta eftir höfundi "Provan, Sella A"

Atriði 1-2 af 2

Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? : An observational study from the Nordic countries

Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan K; Provan, Sella A; Nordström, Dan; Hokkanen, Anna-Mari; Österlund, Jenny; Kristianslund, Eirik; Kvien, Tore K; Guðbjörnsson, Björn; Hetland, Merete Lund; Michelsen, Brigitte; Jacobsson, Lennart; Askling, Johan; Lindström, Ulf (2022-06-20)

OBJECTIVES: The positioning of secukinumab in the treatment of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) is debated, partly due to a limited understanding of the comparative safety of available treatments. We aimed to assess risk ...
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : results from four Nordic countries

Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella A; Glintborg, Bente; Hetland, Merete Lund; Grøn, Kathrine Lederballe; Peltomaa, Ritva; Relas, Heikki; Turesson, Carl; Guðbjörnsson, Björn; Michelsen, Brigitte; Askling, Johan (2022-03-22)

OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical ...

Atriði 1-2 af 2

Leita